reMYND NV

📍 Heverlee, Belgium🗓 Founded 2002👥 53 employees💰 Last funded Apr 2022
Biotechnology🌐 remynd.com
Website LinkedIn
reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models. For more information please visit www.remynd.com Alternatively, please contact Koen De Witte (Managing Director - pipeline@remynd.com) to hear more about reMYND's pipeline or Bart Roucourt (Manager Contact Research - cro@remynd.com) to get more information on reMYND's Contract Research Offering.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
2002
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Belgium
2
Netherlands
1
Investor activity2017–2022 · investors recorded per year
201712021120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in reMYND NV?
reMYND NV has 3 investors on record on gritt.io.
When did reMYND NV last raise funding?
The most recent investment in reMYND NV recorded on gritt.io was in April 2022.
When was reMYND NV founded?
reMYND NV was founded in 2002.
What industry is reMYND NV in?
reMYND NV operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is reMYND NV based?
reMYND NV is headquartered in Heverlee, Belgium.